Additive endocrine therapy for advanced breast cancer – back to the future

References

• Iveson TJ, Ahearn J, Smith IE. Response to third-line endocrine treatment for advanced breast cancer. Eur J Cancer 1993; 29A: 572–4
   PubMedGoogle Scholar
• Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997; 80: 218–24
   PubMed Web of Science ®Google Scholar
• Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment. Breast Cancer Res Treat 2001; 67: 111–6
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, et al. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. Cancer Res 2009; 69: 67S–68S
   Google Scholar
• Steinach, E, Kun, H. Transformation of male sex hormones into a substance with the action of a female hormone. Lancet 1937; II:845.
   Google Scholar
• Jensen, EV, DeSombre, ER, Jungblut, PP. Estrogen receptors in hormone-responsive tissues and tumors. RW Wissler, TL Dao, S Wood, Jr. Endogenous factors influencing host-tumor balance. University of Chicago Press; 1967; 15–30.
   Google Scholar
• McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978; 38: 4289–91
   PubMed Web of Science ®Google Scholar
• Talman MLM, Rasmussen BB, Andersen J, Christensen IJ. Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol 2008; 47: 789–94
   PubMed Web of Science ®Google Scholar
• Rose, C, Thorpe, SM, Andersen, KW, Pedersen, BV, Mouridsen, HT, Blichert-Toft, M, , et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985:16–9.
   PubMedGoogle Scholar
• Degenshein GA, Bloom N, Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer 1980; 46: 2789–93
   PubMed Web of Science ®Google Scholar
• McGuire WL, Horwitz KB, Pearson OH, Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977; 39: 1934–47
   Google Scholar
• Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol 1998; 11: 155–68
   PubMed Web of Science ®Google Scholar
• Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–81
   PubMed Web of Science ®Google Scholar
• Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 1975; 189: 726–7
   PubMed Web of Science ®Google Scholar
• Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973–9
   PubMed Web of Science ®Google Scholar
• Lønning PE, Helle SI, Johannessen DC, Ekse D, Adlercreutz H. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996; 39: 335–41
   PubMed Web of Science ®Google Scholar
• Suzuki M, Ishida H, Shiotsu Y, Nakata T, Akinaga S, Takashima S, et al. Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients. J Ster Biochem Mol Biol 2009; 113: 195–201
   PubMedGoogle Scholar
• Tseng L, Mazella J, Lee LY, Stone ML. Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. J Steroid Biochem 1983; 19: 1413–7
   PubMedGoogle Scholar
• Lønning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990; 35: 355–66
   PubMedGoogle Scholar
• Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001; 86: 5060–6
   PubMed Web of Science ®Google Scholar
• Lundgren S, Helle SI, Lønning PE. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 1996; 2: 1515–21
   PubMed Web of Science ®Google Scholar
• van Landeghem AJJ, Poortman J, Nabuurs M, Thijssen JHH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res 1985; 45: 2900–4
   PubMed Web of Science ®Google Scholar
• Dorgan JF, Longcope C, Franz C, Stanczyk FZ, Chang LC, Stephenson HE, et al. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606–16
   PubMedGoogle Scholar
• Lønning, PE, Helle, H, Duong, NK, Ekse, D, Aas, T, Geisler, J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009;117:31–41.
   PubMed Web of Science ®Google Scholar
• Miller WR, Telford J, Love C, Leonard RCF, Hillier S, Gundacker H, et al. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast 1998; 7: 273–6
   Web of Science ®Google Scholar
• Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7: 1230–6
   PubMed Web of Science ®Google Scholar
• Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbo Y, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clinical Cancer Res 2008; 14: 6330–5
   PubMed Web of Science ®Google Scholar
• Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104–7
   Google Scholar
• Haddow A, Watkinson JM, Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. Brit Med J 1944; 2: 393–8
   PubMedGoogle Scholar
• Binnie GG. Regression of tumors following treatment by stilboestrol and x-ray therapy, with notes on case of breast tumour which regressed with stilboestrol alone. Brit J Radiol 1944; 17: 42–5
   Google Scholar
• Luft R, Olivecrona H, Sjögren B. Hypophysektomy in man. Nord Med 1952; 14: 351–4
   Google Scholar
• Dao TL, Huggins C. Bilateral adrenalectomy in the treatment of cancer of the breast. Arch Surg 1955; 71: 645–57
   Web of Science ®Google Scholar
• Nevinny HB, Haines CR, Dederick MM, Hall TC. Comparative study of 6-dehydro-17alpha-methyltestosterone + testosterone propionate in human breast cancer. Cancer 1964; 17: 95–9
   PubMed Web of Science ®Google Scholar
• Lemon HM. Prednisone therapy of advanced mammary cancer. Cancer 1959; 12: 93–107
   PubMed Web of Science ®Google Scholar
• Lundgren S. Progestins in breast cancer treatment. Acta Oncol 1992; 31: 709–22
   PubMed Web of Science ®Google Scholar
• Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982; 96: 94–101
   PubMed Web of Science ®Google Scholar
• Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Brit J Cancer 1971; 25: 270–5
   PubMed Web of Science ®Google Scholar
• Cash R, Brough AJ, Cohen MNP, Satoh PS. Aminoglutethimide (Elipten-Ciba) is an inhibitor of adrenal steroidogenesis: Mechanism of action and therapeutic trial. J Clin Endocrinol Metab 1967; 27: 1239–48
   PubMed Web of Science ®Google Scholar
• Santen RJ, Lipton A, Kendall J. Successful medical adrenalectomy with aminoglutethimide. JAMA 1974; 230: 1661–5
   PubMed Web of Science ®Google Scholar
• Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984; 36: 245–76
   PubMed Web of Science ®Google Scholar
• Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocrine Rev 1990; 11: 221–65
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R, et al. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996; 348(9036)1189–96
   PubMedGoogle Scholar
• Nillius SJ. The therapeutic uses of gonadotrophin-releasing hormone and its analogues. Clinical Endocrinology I, C Beardwell, GL Robertson. Butterworths, London 1981; 211–37
   Google Scholar
• Lønning PE, Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol/Haematol 1995; 21: 158–93
   Google Scholar
• Fracchia, AA, Randall, HT, Harrow, JH. The results of adrenalectomy in advanced breast cancer in 500 consecutive patients. Surg Gynecol Obstetr 1967:747–56.
   PubMedGoogle Scholar
• Fracchia, AA, Farrow, JH, Miller, TR, Tollefsen, RH, Greenberg, EJ, Knapper, WH. Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast. Surg Gynecol Obst 1971:241–6.
   PubMedGoogle Scholar
• Bonneterre J, Peyrat J, Demaille A. Is human breast cancer prolactin-dependent?. Rev Endocrine-Related Cancer 1990; 35: 25–30
   Google Scholar
• Dowsett M, Cantwell B, Lal A, Jeffcoate SL, Harris AL. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab 1988; 66: 672–7
   PubMed Web of Science ®Google Scholar
• Newsome HH, Brown PW, Terz JJ, Lawrence WJ. Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer 1977; 39: 542–6
   PubMed Web of Science ®Google Scholar
• Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, et al. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 1981; 305: 545–51
   PubMed Web of Science ®Google Scholar
• Wells SAJ, Worgul TJ, Samojlik E, Boucher AE, Lipton A, Harvey H, et al. Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast. Cancer Res 1982; 42(Suppl)3454s–7s
   PubMedGoogle Scholar
• Lønning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. Eur J Cancer 2009; 45: 527–35
   PubMed Web of Science ®Google Scholar
• Taylor SG, Ayer JP, Morris RS. Cortical steroids in treatment of cancer. JAMA 1956; 144: 1058–64
   Google Scholar
• Kofman S, Nagamani D, Buenger RF, Taylor SG. The use of prednisolone in the treatment of disseminated breast carcinoma. Cancer 1958; 11: 226–32
   PubMed Web of Science ®Google Scholar
• NissenMeyer R, Vogt JH. Cortisone treatment of metastatic breast cancer. Acta Unio Int Contra Cancrum 1959; 15: 1140–4
   PubMedGoogle Scholar
• Lønning PE. New endocrine drugs for treatment of advanced breast cancer. Acta Oncol 1990; 29: 379–86
   PubMed Web of Science ®Google Scholar
• Lønning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35: 685–710
   PubMed Web of Science ®Google Scholar
• Samojlik E, Veldhuis JD, Wells SA, Santen RJ. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J Clin Invest 1980; 65: 602–12
   PubMed Web of Science ®Google Scholar
• Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257–65
   PubMed Web of Science ®Google Scholar
• Lundgren S, Gundersen S, Klepp R, Lønning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 1989; 14: 201–6
   PubMed Web of Science ®Google Scholar
• Andersen J, Kamby C, Ejlertsen B, Cold S, Ewertz M, Jacobsen EH, et al. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Oncol 2008; 47: 718–24
   PubMed Web of Science ®Google Scholar
• Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999; 17: 3418–25
   PubMed Web of Science ®Google Scholar
• Lønning PE, Bajetta E, Murray R, TubianaHulin M, Eisenberg PD, Mickiewicz E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000; 18: 2234–44
   PubMed Web of Science ®Google Scholar
• Brufman G, Isacson R, Haim N, Gez E, Sulkes A. Megestrol-acetate in advanced breast-carcinoma after failure to tamoxifen and/or aminoglutethimide. Oncology 1994; 51: 258–61
   PubMed Web of Science ®Google Scholar
• Aisner J, Tchekmedyian NS, Moody M, Tait N. High-dose megestrol acetate for the treatment of advanced breast cancer: Dose and toxicities. Sem Hematol 1987; 24(2,Suppl. 1)48–55
   PubMedGoogle Scholar
• Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989; 49: 7162–7
   PubMed Web of Science ®Google Scholar
• Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, et al. Breast cancer: From estrogen to androgen receptor. Mol Cell Endocrinol 2002; 193: 121–8
   PubMed Web of Science ®Google Scholar
• Nosaquo ND. Androgens and estrogens in the treatment of disseminated mammary carcinoma. JAMA 1960; 172: 135–47
   Google Scholar
• Segaloff A, Meyer KK, Cuningha M, Weeth JB. Hormonal therapy in cancer of breast. 23. Effect of 7alpha-methyl-19-nortestosterone acetate + testosterone propionate on clinical course + hormonal excretion. Cancer 1964; 17: 1248
   PubMed Web of Science ®Google Scholar
• Volk H, Deupree RH, Goldenberg IS, Wilde RC, Carabasi RA, Escher GC. A dose response evaluation of delta-1-testololactone in advanced breast cancer. Cancer 1974; 33: 9–13
   PubMed Web of Science ®Google Scholar
• Barone RM, Shamonki IM, Siiteri PK, Judd HL. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using Ð1-testoloclactone. J Clin Endocrinol Metab 1979; 49: 672–6
   PubMed Web of Science ®Google Scholar
• Johannessen DC, Engan T, Salle Ed, Zurlo MG, Paolini J, Ornati G, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 1997; 3: 1101–8
   PubMed Web of Science ®Google Scholar
• Macedo LF, Guo ZY, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006; 66: 7775–82
   PubMed Web of Science ®Google Scholar
• Suzuki T, Miki Y, Moriya T, Akahira JI, Ishida T, Hirakawa H, et al. 5 alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 2007; 120: 285–91
   PubMed Web of Science ®Google Scholar
• Haddow A. Influence of certain polycyclic hydrocarbons on the growth of the jensen rat sarcoma. Nature 1935; 136: 868–9
   Google Scholar
• Kennedy BJ, Nathanson IT. Effects of intensive sex steroid hormone therapy in advanced breast cancer. JAMA 1953; 152: 1135–41
   PubMed Web of Science ®Google Scholar
• Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, et al. Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. JAMA 1977; 237: 2079–85
   PubMedGoogle Scholar
• Kennedy BJ. Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer 1962; 15: 641–8
   PubMedGoogle Scholar
• Feldman EB, Silverstein JN, Nayak RV, Carter AC. Antitumor endocrine and metabolic effects of 16alpha-estradiol dispropionate in women with breast cancer. Cancer 1962; 15: 1073–5
   PubMedGoogle Scholar
• Heuson, JC, Engelsman, E, Blank-van der Wijst, J, Maass, H, Drochmans, A, Michel, J,, et al. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: An E.O.R.T.C. study. Brit Med J 1975:711–3.
   PubMedGoogle Scholar
• Matelski H, Huberman M, Zipoli T, Greene R, Lokich J. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 1985; 8: 128–33
   PubMedGoogle Scholar
• Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, et al. Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304: 16–21
   PubMed Web of Science ®Google Scholar
• Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999; 54: 117–22
   PubMed Web of Science ®Google Scholar
• Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 2005; 39: 294–300
   PubMed Web of Science ®Google Scholar
• Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4595–601
   PubMed Web of Science ®Google Scholar
• Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995; 80: 2918–25
   PubMed Web of Science ®Google Scholar
• Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005; 95: 167–72
   PubMed Web of Science ®Google Scholar
• Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li TY, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Nat Cancer Inst 2005; 97: 1746–59
   PubMed Web of Science ®Google Scholar
• Jordan VC. The 38th David A. Karnofsky lecture: The paradoxical actions of estrogen in breast cancer – survival or death?. J Clin Oncol 2008; 26: 3073–82
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Aromatase inhibitors: Future directions. J Steroid Biochem Mol Biol 2005; 95: 183–7
   PubMed Web of Science ®Google Scholar
• Yue W, Fan P, Wang JP, Li YB, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106: 102–10
   PubMed Web of Science ®Google Scholar
• Samojlik E, Santen RJ, Worgul TJ. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. Clin Endocrinol 1984; 20: 43–51
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Helle H, Ekse D, Dowsett M, et al. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 2005; 96: 415–22
   PubMedGoogle Scholar
• Mahtani RL, Stein A, Vogel CL. High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): “Back to the future”. Cancer Res 2009; 69: 386S–7S
   Google Scholar
• Helle SI, Omsjø IH, Hughes SCC, Botta L, Hüls G, Holly JMP, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study. Clin Endocrinol 1996; 45: 727–32
   PubMed Web of Science ®Google Scholar